Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like Spinraza (nusinersen) for spinal muscular atrophy (SMA) and its multiple ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

TOKYO – Japan is expected to lower the price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co.

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. Read more on BIIB stock here.

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more ...

The drugs — Eli Lilly’s Kisunla (also known as donanemab) and Biogen and Eisai’s Leqembi (lecanemab) — won approval from U.K. regulators last year, with the Medicines and Healthcare ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

The drugs — Eli Lilly’s Kisunla and Biogen and Eisai’s Leqembi — last year won approval from the U.K. Medicines and Healthcare products Regulatory Agency, which found the benefits ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.